Publications by authors named "Katarzyna Karlowicz"
Introduction: Ophthalmological manifestations (O-EIM) are one of the extraintestinal manifestations (EIM) of inflammatory bowel disease (IBD), although their frequency and potential relationship with disease activity and treatment remain underestimated.
Aim: The aim of this screening questionnaire was to assess the number of EIM, including O-EIM, among patients with IBD.
Material And Methods: 436 patients with IBD and 102 patients without IBD were included in this single-centre retrospective study.
Article Synopsis
- Inflammatory bowel disease (IBD) patients take various immunosuppressive drugs, and their impact on SARS-CoV-2 vaccine antibody levels is unclear.
- A study of 346 vaccinated IBD patients showed that antibody levels decrease over time and are negatively correlated with certain treatments, including infliximab, adalimumab, and vedolizumab.
- Findings suggest IBD patients may have lower persistence of SARS-CoV-2 antibodies and might need booster shots, emphasizing the importance of educating patients about continued vaccination.
Introduction: Patients with Inflammatory Bowel Disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are at high risk of developing malignancies, so prevention and adherence to cancer screening may improve detection. The aim of this study was to assess compliance with medical recommendations, especially primary and secondary prevention of cancer.
Methods: This one-center cross-sectional study was carried out between June and December 2021 amongst patients at the Department of Internal Medicine and Gastroenterology, IBD Division, National Medical Institute of Ministry of Interior Affairs and Administrations, or the outpatient clinic.
Aim: The aim of the study was to assess the effectiveness of a patented preparation of sodium butyrate in the triglyceride matrix at reducing clinical symptoms and improving quality of life in patients with irritable bowel syndrome (IBS).
Material And Methods: In this prospective multicenter clinical trial, we observed a total of 3000 non-hospitalized patients with confirmed IBS who were treated with sodium butyrate in a triglyceride matrix at a dosage of 150 mg twice a day for 12 weeks. The primary outcome was to evaluate the efficacy of sodium butyrate at reducing the severity of clinical symptoms and improving quality of life in patients with IBS.